Raymond James analyst Danielle Brill reinstates Immunovant (NASDAQ:IMVT) with a Outperform and announces $36 price target.
Raymond James Reinstates Outperform on Immunovant, Announces $36 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.